Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation

P. West, M. Schmiedeskamp, H. Neeley, J. Oberholzer, E. Benedetti, B. Kaplan

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Cytomegalovirus (CMV) infection is a major complication following solid organ transplantation resulting in significant morbidity and mortality. The guidelines published in 2004 have recommendations for therapy; however, the frequency of resistant CMV infection is increasing and therapy is not clearly defined. There are a few alternatives to ganciclovir such as foscarnet, cidofovir, and leflunomide; however, their use is limited by adverse effects. This report summarizes the successful use of high-dose ganciclovir for the treatment of a resistant CMV caused by UL97 mutation.

Original languageEnglish (US)
Pages (from-to)129-132
Number of pages4
JournalTransplant Infectious Disease
Volume10
Issue number2
DOIs
StatePublished - Apr 1 2008

Keywords

  • Cytomegalovirus
  • Ganciclovir
  • Resistance
  • Transplant
  • UL97 mutation

ASJC Scopus subject areas

  • Infectious Diseases
  • Transplantation

Fingerprint Dive into the research topics of 'Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation'. Together they form a unique fingerprint.

  • Cite this

    West, P., Schmiedeskamp, M., Neeley, H., Oberholzer, J., Benedetti, E., & Kaplan, B. (2008). Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation. Transplant Infectious Disease, 10(2), 129-132. https://doi.org/10.1111/j.1399-3062.2007.00249.x